65,437 trials
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Objective Tumor Response — 4; 8; 8; 32 Participants
Malaria, Falciparum
Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat…
Parkinson's Disease
Primary: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary — -0.76; -1.25 hours — p=0.0228
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Objective Tumor Response — 21; 32; 17; 1 participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. — 159; 175; 111; 107 participants
Lymphocytic Leukemia, Chronic
Primary: Bone Marrow Response — -20.0; -20.0 Percentage of infiltration
Asthma
Primary: Proportion of Participants With Severe Asthma Exacerbations — 0.52; 0.55 proportion of participants
Metabolic Syndrome
Primary: Insulin Sensitivity (Si) — 3.03; 3.15 104xmin-1/microU/ml — p=<0.05
Pain · Obesity · Surgery
Primary: Quality of Recovery 40 Score — 170; 175.5 units on scale 40 (low) - 200 (high) — p=.05
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
Alcohol Abuse
Primary: Alcohol Consumption in Drinks/Week. — 83.43; 75.97 number of drinks
Myocardial Infarction
Primary: Myocardial Blood Flow at Baseline and 3-month Follow-up — 0.62; -0.27; 0.44; 0 ml/min/g
Falciparum Malaria
Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants
Ondansetron
Primary: Change in QTc Interval With Ondansetron Administration — 19.7 mS
Diabetes
Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005